• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Progyny Inc.

    3/3/25 5:29:05 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email
    S-8 1 progyny-2025sx8.htm S-8 Document
    As filed with the Securities and Exchange Commission on March 3, 2025.

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    Progyny, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware27-2220139
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    1359 Broadway
    New York, New York 10018
    (212) 888-3124
    (Address of Principal Executive Offices)
    (Zip Code)

    Progyny, Inc. 2019 Equity Incentive Plan
    Progyny, Inc. 2019 Employee Stock Purchase Plan
    (Full title of the plan)

    Allison Swartz
    General Counsel
    Progyny, Inc.
    1359 Broadway
    New York, New York 10018
    (212) 888-3124
    (Name and address of agent for service)
    (Telephone number, including area code, of agent for service)

    Copies to:
    Andrew P. Gilbert, Esq.
    Rita Patel, Esq.
    DLA Piper LLP (US)
    1251 Avenue of the Americas
    New York, NY 10020-1104
    (212) 335-4500

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☒
    Non-accelerated filer ☐
    Accelerated filer ☐
    Smaller reporting company ☐
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐




    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Progyny, Inc. (the “Registrant”) is filing this Registration Statement with the U.S. Securities and Exchange Commission (the “Commission”) to register (i) 3,461,436 additional shares of its common stock under the Registrant’s 2019 Equity Incentive Plan, as amended (the “2019 Plan”), pursuant to the provisions of the 2019 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2019 Plan on January 1, 2025 and that have become available for issuance under the 2019 Plan as a result of the forfeiture, termination, expiration or repurchase of stock options or other stock awards or shares withheld or reacquired to satisfy the exercise price or tax withholding obligations associated with any award that had been granted under the Registrant’s 2017 Equity Incentive Plan, as amended, and (ii) 853,106 additional shares of its common stock under the Registrant’s 2019 Employee Stock Purchase Plan (the “2019 ESPP” and together with the 2019 Plan, the “Plans”), pursuant to the provisions of the 2019 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2019 ESPP on January 1, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    The Registrant previously registered shares of its common stock for issuance (i) under the Plans on a Registration Statement on Form S-8 filed with the Commission on October 25, 2019 (File No. 333-234342), (ii) under the 2019 Plan on a Registration Statement on Form S-8 dated March 10, 2020 but deemed filed with the Commission on March 11, 2020 (File No. 333-237072), (iii) under the Plans on a Registration Statement on Form S-8 filed with the Commission on March 2, 2021 (File No. 333-253787), (iv) under the Plans on a Registration Statement on Form S-8 filed with the Commission on March 2, 2022 (File No. 333-263240), (v) under the Plans on a Registration Statement on Form S-8 filed with the Commission on March 1, 2023 (File No. 333-270198), and (vi) under the Plans on a Registration Statement on Form S-8 filed with the Commission on February 29, 2024 (File No. 333-277528). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above except as set forth below.
    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025.
    (b) The description of the Registrant’s common stock which is contained in a registration statement on Form 8-A filed on October 22, 2019 (File No. 001-39100) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.
    (c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.




    ITEM 8.EXHIBITS

    Incorporated by Reference
    Exhibit
    Number
    DescriptionSchedule
    Form
    File NumberExhibitFiling Date
    4.1
    Amended and Restated Certificate of Incorporation of Progyny, Inc.
    8-K
    001-39100
    3.1
    October 31, 2019
    4.2
    Second Amended and Restated Bylaws of Progyny, Inc.
    10-Q
    001-39100
    3.1
    November 12, 2024
    4.3
    Form of Registrant’s Common Stock Certificate.
    S-1/A
    333-233965
    4.1
    October 15, 2019
    5.1*
    Opinion of DLA Piper LLP (US).
    23.1*
    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
    23.2*
    Consent of DLA Piper LLP (US) (included in Exhibit 5.1).
    24.1*
    Power of Attorney (included on the signature page of this Form S-8).
    99.1
    Progyny, Inc. 2017 Equity Incentive Plan and forms of agreements thereunder.
    S-8
    333-233965
    99.2
      October 25, 2019
    99.2
    Amendment No. 1 to the Progyny, Inc. 2017 Equity Incentive Plan.
    10-K
    001-39100
    10.4
    March 1, 2021
    99.3
    Progyny, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder.
    S-1/A
    333-233965
    10.4
    October 15, 2019
    99.4
    Amendment No. 1 to the Progyny, Inc. 2019 Equity Incentive Plan.
    10-K
    001-39100
    10.6
    March 1, 2021
    99.5
    Progyny, Inc. 2019 Employee Stock Purchase Plan.
    S-1/A
    333-233965
    10.5
    October 15, 2019
    107*
    Filing Fee Table.
    *   Filed herewith





















    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 3, 2025.


    PROGYNY, INC.
    By:/s/ Peter Anevski
    Name:Peter Anevski
    Title:Chief Executive Officer











































    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Anevski and Mark Livingston, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits and schedules thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Peter Anevski
    Peter Anevski
    Chief Executive Officer and Director
    (Principal Executive Officer)
    March 3, 2025
    /s/ Mark Livingston
    Mark Livingston
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    March 3, 2025
    /s/ David Schlanger
    David Schlanger
    Director
    March 3, 2025
    /s/ Jeffrey Park
    Jeffrey Park
    Lead Independent Director
    March 3, 2025
    /s/ Fred Cohen, M.D., D.Phil.
    Fred Cohen, M.D., D.Phil.
    Director
    March 3, 2025
    /s/ Lloyd Dean
    Lloyd Dean
    Director
    March 3, 2025
    /s/ Kevin Gordon
    Kevin Gordon
    Director
    March 3, 2025
    /s/ Roger Holstein
    Roger Holstein
    Director
    March 3, 2025
    /s/Debra Morris
    Debra Morris
    Director
    March 3, 2025
    /s/ Norman Payson, M.D.
    Norman Payson, M.D.
    Director
    March 3, 2025
    /s/ Cheryl Scott
    Cheryl Scott
    Director
    March 3, 2025

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Financials

    Live finance-specific insights

    See more
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Fourth Quarter 2024 Results

      Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

      2/27/25 4:01:22 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/8/25 4:22:47 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SCHEDULE 13G filed by Progyny Inc.

      SCHEDULE 13G - Progyny, Inc. (0001551306) (Subject)

      4/29/25 3:52:52 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      12/6/24 10:11:35 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      11/14/24 4:31:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      2/14/24 6:29:49 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Cummings Melissa B was granted 41,667 shares (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:08:28 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3 filed by new insider Cummings Melissa B

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:01:18 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • New insider Clapp Geoffrey claimed ownership of 28,694 shares (SEC Form 3)

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:00:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump

      NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and

      1/28/25 8:44:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care